A Phase 4 interventional study of Valsartan + HCTZ and Valsartan in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in United States. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 50th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2008, is one of 67 in phase 4, and was the 94th registered.
6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 384 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 100th largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 67 in phase 4, and was the 138th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(patients initiated on valsartan)
Drug: Valsartan
(patients initiated on HCTZ)
Drug: HCTZ
(patients initiated on Valsartan+HCTZ)
Drug: Valsartan + HCTZ
Drug pages: Valsartan · Hydrochlorothiazide
At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
Change From Baseline to Week 4 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)
Time frame: Baseline and Week 4
Change From Baseline to Week 4, 8, 12 and 16 in Office Cuff Mean Sitting Diastolic Blood Pressure (MSDBP)
Time frame: Baseline and Weeks 4, 8, 12 and 16
Change From Baseline to Weeks 8, 12 and 16 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)
Time frame: Baseline and Weeks 8, 12, and 16
Cumulative Percentage of Patients Achieving the Blood Pressure Control of < 140/90 mmHg
Cumulative refers to achieving of blood pressure control before or at the corresponding visit.
Time frame: Weeks 4, 8, 12 and 16
Cumulative Percentage of Patients Achieving Blood Pressure Goal (MSSBP < 140 mmHg)
Cumulative refers to achieving blood pressure goal before or at the corresponding visit.
Time frame: Weeks 4, 8, 12 and 16
Time in Weeks to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg])
Time frame: During 16 weeks
| Milestone | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Started | 128 | 128 | 128 |
| Completed | 92 | 97 | 99 |
| Not completed | 36 | 31 | 29 |
| Withdrew: Adverse event | 8 | 7 | 8 |
| Withdrew: Unsatisfactory therapeutic effect | 11 | 11 | 7 |
| Withdrew: Protocol deviation | 6 | 2 | 3 |
| Withdrew: Withdrawal by subject | 10 | 11 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Administrative problems | 1 | 0 | 1 |
| mm Hg | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Baseline | 166.2 ± 11.07 | 164.5 ± 11.84 | 164.5 ± 11.86 |
| Week 4 | 157.5 ± 19.71 | 150.9 ± 18.41 | 147.1 ± 18.35 |
| Change in MSSBP from Baseline to Week 4 | -8.6 ± 19.47 | -13.6 ± 16.81 | -17.3 ± 17.61 |
| mm Hg | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Baseline | 84.9 ± 9.78 | 85.5 ± 9.09 | 84.8 ± 9.36 |
| Week 4 | 81.0 ± 10.61 | 81.6 ± 10.97 | 77.8 ± 9.66 |
| Change in MSDBP from Baseline to Week 4 | -3.9 ± 9.08 | -3.9 ± 10.24 | -7.1 ± 8.80 |
| Week 8 | 78.3 ± 10.33 | 79.1 ± 11.97 | 76.5 ± 9.45 |
| Change in MSDBP from Baseline to Week 8 | -6.6 ± 10.26 | -6.4 ± 10.72 | -8.4 ± 9.68 |
| Week 12 | 77.6 ± 11.0 | 78.1 ± 11.42 | 75.4 ± 8.87 |
| Change in MSDBP from Baseline to Week 12 | -7.3 ± 10.55 | -7.3 ± 10.75 | -9.5 ± 9.66 |
| Week 16 | 77.8 ± 10.34 | 77.9 ± 11.66 | 76.6 ± 8.42 |
| Change in MSDBP from Baseline to Week 16 | -7.1 ± 10.78 | -7.5 ± 10.76 | -8.3 ± 8.62 |
| mm Hg | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Baseline | 166.2 ± 11.07 | 164.5 ± 11.84 | 164.5 ± 11.86 |
| Week 8 | 150.4 ± 20.29 | 147.4 ± 18.69 | 144.2 ± 19.93 |
| Change in MSSBP from Baseline to Week 8 | -15.7 ± 20.43 | -17.1 ± 17.83 | -20.2 ± 19.12 |
| Week 12 | 148.6 ± 21.45 | 145.1 ± 19.38 | 142.0 ± 18.78 |
| Change in MSSBP from Baseline to Week 12 | -17.5 ± 21.16 | -19.4 ± 19.19 | -22.5 ± 19.52 |
| Week 16 | 148.7 ± 20.06 | 144.9 ± 19.59 | 143.5 ± 18.69 |
| Change in MSSBP from Baseline to Week 16 | -17.5 ± 19.62 | -19.7 ± 19.69 | -20.9 ± 18.49 |
Cumulative refers to achieving of blood pressure control before or at the corresponding visit.
| Percentage of Participants | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Week 4 | 25 | 37.3 | 49.21 |
| Week 8 | 40.63 | 50.79 | 63.49 |
| Week 12 | 50 | 61.11 | 69.05 |
| Week 16 | 55.47 | 66.67 | 72.22 |
Cumulative refers to achieving blood pressure goal before or at the corresponding visit.
| Percentage of Participants | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Week 4 | 25 | 38.89 | 49.21 |
| Week 8 | 40.63 | 52.38 | 63.49 |
| Week 12 | 50 | 62.70 | 69.05 |
| Week 16 | 56.25 | 68.25 | 72.22 |
| Weeks | Valsartan | HCTZ | Valsartan + HCTZ |
|---|---|---|---|
| Time in Weeks to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg]) | 12.0 (8.0 to 12.0) | 8.0 (7.0 to 12.0) | 4.0 (3.0 to 8.0) |
Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan + HCTZ | — | 3/128 (2.3%) | 16/128 (12.5%) |
| HCTZ | — | 4/128 (3.1%) | 27/128 (21.1%) |
| Valsartan | — | 3/128 (2.3%) | 23/128 (18%) |
| Event | Valsartan + HCTZ | HCTZ | Valsartan |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/128 | 1/128 | 0/128 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/128 | 0/128 | 1/128 |
| AppendicitisInfections and infestations | 0/128 | 0/128 | 1/128 |
| PneumoniaInfections and infestations | 1/128 | 0/128 | 0/128 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/128 | 0/128 | 1/128 |
| Spinal fractureInjury, poisoning and procedural complications | 0/128 | 0/128 | 1/128 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/128 | 1/128 | 0/128 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/128 | 0/128 | 0/128 |
| Cerebral haemorrhageNervous system disorders | 0/128 | 0/128 | 1/128 |
| SyncopeNervous system disorders | 1/128 | 1/128 | 0/128 |
| Event | Valsartan + HCTZ | HCTZ | Valsartan |
|---|---|---|---|
| FatigueGeneral disorders | 5/128 | 10/128 | 5/128 |
| DizzinessNervous system disorders | 5/128 | 8/128 | 9/128 |
| HeadacheNervous system disorders | 6/128 | 9/128 | 3/128 |
| Upper respiratory tract infectionInfections and infestations | 1/128 | 4/128 | 8/128 |
| Age Continuous(years) | Valsartan | HCTZ | Valsartan + HCTZ | Total |
|---|---|---|---|---|
| Mean | 77.7 ± 4.22 | 77.7 ± 4.80 | 77.2 ± 3.99 | 77.5 ± 4.34 |
| Age, Customized(participants) | Valsartan | HCTZ | Valsartan + HCTZ | Total |
|---|---|---|---|---|
| 70-75 years | 41 | 41 | 44 | 126 |
| 76-80 years | 60 | 56 | 65 | 181 |
| >80 years | 27 | 31 | 19 | 77 |
| Sex: Female, Male(Participants) | Valsartan | HCTZ | Valsartan + HCTZ | Total |
|---|---|---|---|---|
| Female | 81 | 62 | 71 | 214 |
| Male | 47 | 66 | 57 | 170 |
The record gives a start of Apr 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Hydrochlorothiazide